$Cassava Sciences (SAVA.US)$ Over 1,587 patients now enrolle...
$Cassava Sciences(SAVA.US$ Over 1,587 patients now enrolled in Phase 3 studies of simufilam in Alzheimer’s disease, an increase of over 340 patients in the last three months.
Completion of patient enrollment for Phase 3 program still expected Q4 2023.
$168.4 Million in Cash and Cash Equivalents at June 30, 2023.
Completion of patient enrollment for Phase 3 program still expected Q4 2023.
$168.4 Million in Cash and Cash Equivalents at June 30, 2023.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Moo2YouToo : At this enrollment rate, we should see complete enrollment by September 15th. buying several options, in hopes of it being a catalyst.